Neurogene (NGNE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and lead program

• Focuses on genetic medicines for rare neurologic diseases using a biology-first approach.

• Lead candidate NGN-401 targets Rett syndrome, a multi-billion dollar market with 15,000–20,000 patients in the US and Europe.

• Rett syndrome causes developmental regression and severe motor and communication impairments in children.

• NGN-401 aims to improve key domains such as hand function, gross motor skills, and communication.

Clinical progress and data

• Pivotal study for NGN-401 began dosing in Q4 2025; enrollment and dosing expected to complete in Q2 2026.

• Phase I/II data showed 35 milestones gained across 8 participants, averaging 4 skills per patient, with durable and multi-domain improvements.

• Upcoming catalyst: 12-month data from all 10 dosed patients to be presented in mid-2026.

• Success defined as multi-domain, durable improvements; FDA threshold is 7 of 20 patients (35%) showing benefit, with study powered at 99%.

Differentiation and technology

• NGN-401 uses a full-length human MECP2 gene and proprietary technology to regulate expression, minimizing toxicity.

• Delivery via ICV ensures drug reaches neurons in the brain; caregivers and payers support this route due to efficacy.

• Monitoring protocols and dose reduction have addressed prior safety concerns, with no HLH events at current dose.

• Observed nerve conduction issues are considered a class effect of AAV gene therapies, not specific to NGN-401 or its delivery method.